Semaglutide vs. Tirzepatide Comparison Guide

Suggested URL slug: `/blog/semaglutide-vs-tirzepatide-chattanooga`

Meta description (≤155 chars): A board-certified Chattanooga physician compares semaglutide and tirzepatide for weight loss — the real trial data, side effects, and how to choose. Free consult.

Related: [[Content-Plan]] [[Summit-Entity]]

If you’ve started researching GLP-1 medication for weight loss here in Chattanooga, you’ve run into the same two names I hear in nearly every first consultation: semaglutide and tirzepatide. You may know them by their brand names — Wegovy and Ozempic for semaglutide, Zepbound and Mounjaro for tirzepatide. And you’ve probably found a dozen websites willing to sell you one or the other in about four minutes, no real conversation required.

I’m Dr. Paul Miranda. I’m a board-certified physician, and at Summit Metabolic Health I personally review every patient’s chart — not a questionnaire run through software, not a nurse queue. So let me give you the honest version of the semaglutide vs. tirzepatide question, the one I’d give you across the desk. Individual results vary, and the right answer depends on your history. But here’s what the evidence actually shows.

Both medications quiet what patients call “food noise” — the constant background hum of thinking about your next meal. They do it through different mechanisms. Semaglutide is a GLP-1 receptor agonist: it mimics a gut hormone that signals fullness to your brain and slows how fast your stomach empties. Tirzepatide does that too, but it’s a dual agonist — it acts on a second hormone receptor (GIP) at the same time. That’s the whole reason these two drugs perform differently in studies.

This matters because it reframes the conversation a lot of my Chattanooga patients arrive with. You did not fail every diet because you lacked willpower. These medications work on the biology of appetite and satiety. That’s not a character upgrade — it’s medicine.

Let me give you real numbers, attributed to the trials they came from, because the marketing you’ve seen rarely does.

For semaglutide, the flagship obesity trial (STEP 1, NEJM 2021) reported a mean body-weight reduction of about 14.9% versus 2.4% on placebo at 68 weeks in adults without diabetes. A newer higher-dose version of semaglutide (Wegovy HD 7.2 mg, STEP UP, FDA-approved March 2026) reported a mean reduction of about 20.7% at 72 weeks.

For tirzepatide, the landmark obesity trial (SURMOUNT-1, NEJM 2022) reported a mean body-weight reduction of about 20.9% at the 15 mg dose over 72 weeks, versus 3.1% on placebo.

The only head-to-head study comparing the two (SURMOUNT-5, NEJM 2025) reported tirzepatide at about 20.2% versus semaglutide at about 13.7% at 72 weeks — and, notably, slightly fewer people stopped tirzepatide for side effects (2.7% vs. 5.6%).

So at standard doses, the trial data favor tirzepatide on average weight loss. But read that sentence carefully: on average. These are group averages from clinical trials. They are not a promise about you. Individual results vary, and I have patients who do beautifully on semaglutide who would never have needed the second drug.

“Better” depends on what we’re solving for — which is exactly why I don’t think this decision belongs to an algorithm.

A few things shift the answer:

– Side effects. Both are GLP-1-class medications, and both most commonly cause gastrointestinal effects — nausea, diarrhea, constipation — concentrated during the dose-escalation phase and usually mild to moderate (STEP and SURMOUNT trial data). In my practice, side effects are a dosing problem far more often than a “this drug is wrong for you” problem — I go into how we manage that in our guide to GLP-1 side effects. We titrate to your tolerance, not a package-insert calendar. – Your other health conditions. Semaglutide carries the deepest cardiovascular and kidney outcomes evidence base (SELECT, NEJM 2023, reported a 20% relative reduction in major cardiovascular events in adults with established heart disease and obesity but no diabetes; FLOW, NEJM 2024, for kidney outcomes in type 2 diabetes). Tirzepatide is the only medication FDA-approved for obstructive sleep apnea in adults with obesity (SURMOUNT-OSA, NEJM 2024). As an ER physician by training, I pay close attention to your heart, not just your weight — and those facts can decide the choice. – Diabetes. If you have type 2 diabetes, expect somewhat less weight loss than the headline numbers — the trials consistently show that pattern with both drugs (STEP 2; SURMOUNT-2). I’d rather you hear that from me up front than feel like you failed at month four.

This is the part the four-minute checkout can’t do. Picking between semaglutide and tirzepatide isn’t really a product choice. It’s a clinical judgment about your biology, your history, and your goals — which is the entire reason I read every chart myself. If you want a shorter side-by-side rundown to bookmark, I keep a quick-reference semaglutide vs. tirzepatide guide updated as new trial data comes in.

Here’s a question almost no program answers honestly: what happens at your goal weight?

The trials are blunt about it. When semaglutide is stopped, a large share of the lost weight returns (STEP 1 extension, Diabetes Obes Metab 2022, reported regaining about two-thirds of the loss off-treatment). Tirzepatide shows the same pattern (SURMOUNT-4, JAMA 2024). But there’s a middle path: a 2026 trial (SURMOUNT-MAINTAIN, Lancet 2026) reported that reducing tirzepatide to a lower maintenance dose held results far better than stopping outright (about 16.6% maintained vs. 9.9% on placebo).

That’s why Summit is built around an exit strategy. The goal is to get you to your weight, then move you into a controlled, physician-directed maintenance plan — so the results hold. It’s also why our program is designed to get cheaper as you get healthier, not to keep you on the highest dose forever. I’ll tell you the same thing on day one that I’ll tell you at goal: this is a chronic condition we manage well, not a switch we flip once.

You can buy semaglutide or tirzepatide from a lot of places, including compounded versions — if cost is part of your decision, see how compounded and brand-name GLP-1s actually differ. What’s hard to find — here in Chattanooga or anywhere — is a board-certified physician who reads your chart, picks the medication with you, adjusts your dose to your tolerance, and plans for the day you no longer need it.

That’s what we do. Monthly video visits with me. Direct access between visits. A real plan for maintenance. Summit Metabolic Health serves patients in Tennessee, Florida, Washington, Ohio, and Georgia — in person and via telehealth.

If you’re trying to decide between semaglutide and tirzepatide, don’t decide alone. Book a free 20-minute consultation and we’ll look at your history together and find the right starting point for you. You can also browse the rest of the Summit Metabolic Health blog for more physician-written breakdowns like this one.

This article is educational and not medical advice. GLP-1 medications carry risks, including a boxed warning regarding thyroid C-cell tumors and contraindications you should review with a physician. Individual results vary. Talk with a qualified clinician about whether treatment is right for you.

– STEP 1 — Wilding JPH et al. NEJM 2021. PMID 33567185 · DOI 10.1056/NEJMoa2032183 — semaglutide ~14.9% mean weight loss at 68 wk. (Established) – STEP UP / Wegovy HD 7.2 mg — Novo Nordisk topline + FDA supplemental NDA 215256s, March 2026 — ~20.7% mean weight loss at 72 wk. (Established; peer-reviewed publication pending — figures from regulatory/press source) – STEP 2 — Davies M et al. Lancet 2021. PMID 33667417 · DOI 10.1016/S0140-6736(21)00213-0 — diabetic blunting of weight loss. (Established) – STEP 1 extension (regain) — Wilding JPH et al. Diabetes Obes Metab 2022. PMID 35441470 · DOI 10.1111/dom.14725 — ~two-thirds regain off-treatment. (Established) – SELECT — Lincoff AM et al. NEJM 2023. PMID 37952131 · DOI 10.1056/NEJMoa2307563 — 20% relative MACE reduction (HR 0.80). (Established) – FLOW — Perkovic V et al. NEJM 2024. PMID 38785209 · DOI 10.1056/NEJMoa2403347 — 24% relative reduction in major kidney events (T2D-CKD, 1.0 mg). (Established) – SURMOUNT-1 — Jastreboff AM et al. NEJM 2022. PMID 35658024 · DOI 10.1056/NEJMoa2206038 — tirzepatide ~20.9% (15 mg) mean weight loss at 72 wk. (Established) – SURMOUNT-2 — Garvey WT et al. Lancet 2023. PMID 37385275 · DOI 10.1016/S0140-6736(23)01200-X — diabetic blunting of weight loss. (Established) – SURMOUNT-4 — JAMA 2024. PMID 38078870 · DOI 10.1001/jama.2023.24945 — regain on withdrawal. (Established) – SURMOUNT-5 (head-to-head) — NEJM 2025. PMID 40353578 · DOI 10.1056/NEJMoa2416394 — tirzepatide −20.2% vs semaglutide −13.7%; AE discontinuation 2.7% vs 5.6%. (Established) – SURMOUNT-OSA — NEJM 2024. PMID 38912654 · DOI 10.1056/NEJMoa2404881 — basis for FDA OSA indication. (Established) – SURMOUNT-MAINTAIN — Horn DB et al. Lancet 2026. PMID 42119587 · DOI 10.1016/S0140-6736(26)00656-2 — dose reduction (~16.6%) vs placebo (~9.9%) maintenance. (Established) – GI side-effect profile — Wharton S et al. Diabetes Obes Metab 2021. PMID 34514682 · DOI 10.1111/dom.14551 (semaglutide pooled tolerability); SURMOUNT-1 safety data (tirzepatide). (Established) – Boxed warning (thyroid C-cell / MTC), contraindications — Wegovy and Zepbound FDA USPI labeling. (Regulatory — Established)